CA Patent

CA2654115A1 — Aqueous suspensions of tmc278

Assigned to Janssen Sciences Ireland ULC · Expires 2007-12-27 · 18y expired

What this patent protects

This invention concerns pharmaceutical compositions for administration vi a intramuscular or subcutaneous injection, comprising micro- or nanoparticle s of the NNRTI compound TMC278, suspended in an aqueous pharmaceutically acc eptable carrier, and the use of such pharmaceutical …

USPTO Abstract

This invention concerns pharmaceutical compositions for administration vi a intramuscular or subcutaneous injection, comprising micro- or nanoparticle s of the NNRTI compound TMC278, suspended in an aqueous pharmaceutically acc eptable carrier, and the use of such pharmaceutical compositions in the trea tment and prophylaxis of HIV infection.

Drugs covered by this patent

Patent Metadata

Patent number
CA2654115A1
Jurisdiction
CA
Classification
—
Expires
2007-12-27
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Sciences Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.